Introduction
Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage Pain in children is mostly underestimated all around the world and often suboptimal managed 1, 2 as a result of injury, illness, during medical procedures and vaccination. Vaccination are considered as the safest and most effective way to prevent serious illness and death 3 .
Vaccination prevent approximately 2.5 million death every year, globally 4 . Various vaccines are given under universal immunisation programme and most of them are administered through parenteral routes. These vaccines are the most common source of unavoidable repeated iatrogenic pain in children. 4 Health care providers are not sensitized pain in neonates and consider it's a benign procedure which require no intervention, on the contrary these repeated injections maycause short-term and long-term effects. They also include physiological changes such as apnoea, bradycardia, tachycardia, skin colour changes, sweating palms, increased respiration rate and muscular tonicity, increased intracranial pressure and behavioural changes, crying, sleep disturbances, feeding problems 5 .
This led to intense anxiety regarding vaccination that may result in non-adherence to the recommended vaccination schedule 6, 7 In last few decades different techniques are evolved to reduce pain during various interventions in neonates which includes nonpharmacological methods like distractions, (video, music, tactile, blowing) sucrose solution or breast milk, patient positioning, vaccination pH and pharmacological like lignocaine gel or spray, EMLA, opioids. EMLA cream was in use from 1980 for relieving pain neonates and children. EMLA Cream (lidocaine 2.5% and prilocaine 2.5%) is an emulsion in which the oil phase is a eutectic mixture of lidocaine and prilocaine in a ratio of 1:1 by weight. It is used to relieve pain during lumber puncture, intra venous, intra arterial cannulation intra muscular injection. 8, 9, 10 It was also used for reduction of pain during vaccination in infants and children. There are very few studies in which effect of EMLA was studied on new born during vaccination. So, the present study was conducted to know the effect of EMLA in reducing pain in newborn during vaccination.
Aims and Objectives
To study the effectiveness of EMLA in alleviating pain during Hepatitis B vaccination given at birth.
Material and methods
The study was conducted in the department of paediatrics Kamla Nehru State Hospital for Mother and Child Shimla. This was a prospective and interventional randamized comparative double blinded study conducted among healthy full term newborns. The study was conducted over a period of one year from 1 st September, 2017 through 31 st August ,2018. The study shah et al observed standardized mean difference of modified behavioral pain scale ranges from -.37 to -.53. Taking this value as reference, the minimum required sample size with 80% power of study and two-sided alpha of 5% was 136 patients per group. So, sample size taken is 280 (140 per group).
Inclusion criteria
Healthy term newborns babies born at Kamla Nehru Hospital during the study period who received hepatitis B vaccine at birth after informed consent regarding the procedure and drugs used. Exclusion criteria 1) Gestation less than 37 weeks, IUGR baby.
2) Newborn with any kind of illness.
3) Newborn requiring any kind of supportive treatment after birth. 4) Newborn with any major congenital malformations. 5) Newborn to those mothers who receive any drug which cause CNS depression in the baby. 6) Newborn whose parent/ guardians refuse to give the consent for the study. The demographic profile of the all the cases was recorded as per a structured case recording format.
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The newborns were randomly divided into two groups. Group 1: Included newborn whom EMLA patch was applied one hour prior to hepatitis B vaccination and act as cases for the study. Group 2: Included newborn whom placebo patch was applied one hour prior to hepatitis vaccination and considered as controls for group 1. Placebo patch used was identical to EMLA patch in its consistency, colour and odour. The parents, as well as observer was not aware of which treatment was received by the neonate making the study double blinded. The person involve in randomization was not involved further in the study. Newborn was laid down on the radiant warmer during whole procedure and was breastfed half hour before vaccination. Vaccine was given to those newborns who were at the 3-4 brazilton stage of arousal 11 on the same surrounding and at the same examination table. EMLA patch or placebo was applied before vaccination depending on the group assigned after randomization. All the injections will be administered by the same staff nurse gently. EMLA cream 1gm were uniformly applied to an area of 1 square inch at the vaccination area (lateral region of right thigh) and covered with an occlusive dressing (Tegaderm) for 60 to 90 minutes 12 , the dressing was removed before procedure, the skin was wiped dry. 0.5ml of Hepatitis B vaccine was be administered intramuscularly at the anterolateral aspect of thigh using 0.60x25mm needle. The primary outcome measures neonatal pain had been assessed using Neonatal Infant Pain Scale (NIPS), a reliable tool to assess neonatal pain 13 .
NIPS score of zero was ensured before vaccination and used as baseline for further comparison. NIPS score was observed immediately after the vaccine, at 30 second, and at one minute after administration of vaccine. Categorical variables were presented in number and percentage (%) and continuous variables was presented as mean ± SD and median. Normality of data was tested by Kolmogorov-Smirnov test. If the normality is rejected then non parametric test was used. Statistical tests were applied as follows: 1) Quantitative variables was compared using Unpaired t-test/Mann-Whitney Test (when the data sets were not normally distributed.) between the two groups.
2) Qualitative variables was compared using
Chi-Square test /Fisher's exact test. A p value of <0.05 was considered statistically significant. The data was entered in MS EXCEL spreadsheet and analysis was done using epi info version 7.2.2
Results
We enrolled a total of 280 participants in our study divided in two groups. Each group had 140 newborns. In group 1 total 140 neonates were participated, out of which 52.14 %were males and 49% were female as compared to group 2 in which out of 140 neonates 50% were male and 50% female.
The difference of gender between two group statistically not significant. Hence both the groups were comparable 
Discussion
Mean±SD of NIPS score in group 1(after application of EMLA before giving Hepatitis B vaccination) at 0,30 and 60 seconds were 4.70±1.22, 1.74±1.19, 1.74±0.65 respectively and the mean of NIPS score of group 2 at 0, 30 and 60 seconds were 5.39±1.33, 3.38±1.12 and 1.56±0.88 respectively, which was significantly lower at all interval with p value of <0.001. It concluded that application of EMLA significantly decrease pain during Hepatitis B vaccine (intramuscular injections). These findings were comparable with study done by Taddio et al who used first cry and duration of cry as pain assessment tool reported a significant decrease in pain in the form of increase in the latency to first cry (MD, 0.90 sec ; 95%CL, .46 to 1.34 ; P<0.001) and decrease in duration of first cry (MD, -1.30sec; 95%Cl, -2.55 to -0.05 ; P=0.04) for infant who received lidocainprilocaine versus a placebo during DPT vaccination at 6 , 10 , 14 weeks, however they did not include newborns in their study 2 .
Similarly, Uhari nurses also reported a lower mean VAS pain score (range, 0-10 cm) (2.5 vs 3.8; P<0.003) and VAS crying score (range, 0-10cm) (2.8 P<0.003) for infant who received lidocaine-prilocaine then for those who received placebo during DPT vaccination in infant. They also did not include newborns in their study and used VAS score for assessment of pain 14 .
In a study of lidocaine -prilocaine and no intervention, Dlli et al, reported a significant reduction in the NIPS score (range, 3-7) (MD, -4.0095% cCl, -4.83 to -3.17;P <0.001) in infants 6 to 12 months of age and in the CHEOPS score (range , 4-13) (P .001; data =NR) during different vaccines Hep B at 0-2weeks, at 1 and 6 month, MMR at 9 months 15 .
Conclusion
Pain perceived during both Hep B and BCG vaccine was less when vaccination was done after EMLA application, which concluded that EMLA is effective modality in alleviating pain during vaccination through intramuscular as well as intradermal route.
Recommendation
EMLA is an effective pain alleviating modality and can be considered as pain reliving modalities during routine immunisation. This will decrease immediate as well as late neurodevelopmental complication in children due to repeated unavoidable pain during vaccination. This will also decrease parents anxiety regarding pain during vaccination and increase adherence to vaccination.
